Trastuzumab (anti-HER2) combined with pertuzumab provides superior benefit in HER2-positive breast cancer compared to trastuzumab alone because:

• A Pertuzumab blocks domain IV of HER2 extracellular domain, the same binding site as trastuzumab, providing additive receptor blockade
• B Pertuzumab blocks domain II of HER2 (the dimerization arm), preventing HER2-HER3 heterodimerization and PI3K/AKT signaling; trastuzumab blocks domain IV preventing HER2 cleavage and activation — complementary non-overlapping epitopes ✓
• C Pertuzumab is an antibody-drug conjugate delivering DM1 cytotoxin in combination with trastuzumab's direct signaling blockade
• D Pertuzumab activates ADCC against HER2 while trastuzumab provides CDC — the two mechanisms synergize for greater tumor killing

Explanation

Trastuzumab and pertuzumab bind to distinct extracellular domains of HER2: trastuzumab binds domain IV near the transmembrane region, preventing proteolytic cleavage and p95-HER2 activation, and also inhibiting PI3K-AKT signaling and activating ADCC. Pertuzumab binds domain II (the dimerization arm), sterically blocking HER2's preferred heterodimerization partner HER3, thereby preventing the most potent HER2-HER3 heterodimer from forming and signaling through PI3K/AKT. This complementary, non-overlapping dual blockade of HER2 is the mechanistic basis for synergy. Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate (separate agent).

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.